While CFIm perturbations undoubtedly affect the polyadenylation landscape, its contribution to GBM remained unclear, as the inference of altered CFIm expression in GBM relative to normal brain was confounded by the variable degree of RNA degradation among samples (Gruber et al., 2018). The gene discussed is CPSF6; the disease is glioblastoma.